Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer
Open accessAbstract
Regulatory T (Treg) cells are potent suppressors that maintain immune homeostasis. Accumulation of Treg can inhibit effective immune responses in cancer patients, leading to tumor development and progression. Despite direct cytotoxicity, several chemotherapeutic drugs have been reported to deplete Treg cells for better prognosis for cancer patients. Treg cells are a heterogenous population with at least three different subsets, nonsuppressive, resting, and activated Treg cells. However, the characteristics of Treg cell subsets in lung cancer patients and how chemotherapy affects Treg cells remain elusive. In this study, we first analyzed Treg cell subsets in peripheral blood samples from 40 nonsmall cell lung cancer (NSCLC) patients and 20 healthy donors. Treg cells, specifically activated Treg cell subset, significantly increased in patients with NSCLC. Compared to nonsuppressive Treg cells, activated Treg cells expressed higher level of CD39 and predominantly produced inhibitory cytokines.In vitro assay showed that docetaxel reduced all three subsets of Treg cells. More importantly, we found docetaxel-based chemotherapy significantly decreased all three Treg subsets after 4 cycles of treatment in 17 NSCLC patients. Taken together, this study revealed dynamic changes of various Treg cell subsets in NSCLC patients before and after chemotherapy, providing activated Treg cells as a potential target for chemotherapy.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Cancer patients have greater vulnerability to infection than people without cancer, owing to immune suppression from the malignancy and treatments such as chemotherapy or surgery.
“Patients with cancer are more susceptible to infection than individuals without cancer because of their systemic immunosuppressive state caused by the malignancy and anticancer treatments, such as chemotherapy or surgery.5, 6, 7, 8”
From Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China (2020) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 40 · Cited by 157
- Authors
- Li, J.-Y., Duan, X.-F., Wang, L.-P., Xu, Y.-J., Huang, L., Zhang, T.-F., Liu, J.-Y., Li, F., Zhang, Z., Yue, D.-L., Wang, F., Zhang, B., & Zhang, Y.
- Affiliations
- First Affiliated Hospital of Zhengzhou University (CN)
- Zhengzhou University (CN)
- Northwestern University (US)
- Corresponding author
- Wang, Li-Ping
- Zhang, Yi
- Venue
- Journal of Immunology Research
- Publisher
- Wiley
- Published
- 2014
- Volume
- 2014
- Pages
- 1-10
- ISSN
- 2314-7156 (ISSN-L)
- 2314-8861
- PMC
- PMC4020463
- OpenAlex
- W2073503439
- Cited by
- 157
- References
- 40
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 13 · 2023: 12 · 2022: 21 · 2021: 29 · 2020: 39 · 2019: 7 · 2018: 7 · 2017: 11 · 2016: 6 · 2015: 3 · 2014: 1
- FWCI
- 3.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Journal of Immunology Research (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- National Natural Science Foundation of China (81171985, 81171986, 20110110001, 112300410153, 122300410155)
- Ministry of Health of the People’s Republic of China (81171985, 81171986, 20110110001, 112300410153, 122300410155)
- Henan University of Science and Technology (81171985, 81171986, 20110110001, 112300410153, 122300410155)
- Innovation Team of the First Affiliated Hospital of Zhengzhou University (81171985, 81171986, 20110110001, 112300410153, 122300410155)
- Higher Education of Henan Province (81171985, 81171986, 20110110001, 112300410153, 122300410155)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- regulatory T cells, docetaxel, non-small cell lung cancer, chemotherapy, CD39, inhibitory cytokines, tumor immunosuppression, Treg depletion
- MeSH terms
- Docetaxel, Aged, Antineoplastic Agents, Phytogenic, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Lymphocyte Depletion, Male, Middle Aged, Neoplasm Staging, Case-Control Studies, Immunophenotyping, Cell Lineage, Taxoids, T-Lymphocytes, Regulatory
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
